Vertex Pharmaceuticals Incorporated is a biotechnology firm primarily dedicated to the discovery, development, and commercialization of therapies for cystic fibrosis (CF). The company offers a range of established CF treatments, such as SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which are prescribed for patients with particular mutations in their cystic fibrosis transmembrane conductance regulator gene. Additionally, TRIKAFTA is marketed for CF patients aged six years or older who carry at least one F508del mutation.